CEGEDIM SA (CGM.PA) Stock Fundamental Analysis

EPA:CGM • FR0000053506

10.4 EUR
-0.2 (-1.89%)
Last: Sep 3, 2025, 07:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CGM. CGM was compared to 10 industry peers in the Health Care Technology industry. CGM has a bad profitability rating. Also its financial health evaluation is rather negative. CGM has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year CGM has reported negative net income.
  • CGM had a positive operating cash flow in the past year.
  • In multiple years CGM reported negative net income over the last 5 years.
  • Each year in the past 5 years CGM had a positive operating cash flow.
CGM.PA Yearly Net Income VS EBIT VS OCF VS FCFCGM.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -1.49%, CGM is in line with its industry, outperforming 45.45% of the companies in the same industry.
  • CGM has a Return On Equity (-5.56%) which is comparable to the rest of the industry.
  • The Return On Invested Capital of CGM (4.46%) is comparable to the rest of the industry.
  • CGM had an Average Return On Invested Capital over the past 3 years of 2.87%. This is significantly below the industry average of 8.41%.
  • The 3 year average ROIC (2.87%) for CGM is below the current ROIC(4.46%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -1.49%
ROE -5.56%
ROIC 4.46%
ROA(3y)-0.25%
ROA(5y)0.74%
ROE(3y)-1.16%
ROE(5y)2.61%
ROIC(3y)2.87%
ROIC(5y)3.89%
CGM.PA Yearly ROA, ROE, ROICCGM.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 -10

1.3 Margins

  • The Operating Margin of CGM (5.75%) is comparable to the rest of the industry.
  • CGM's Operating Margin has declined in the last couple of years.
  • CGM has a worse Gross Margin (20.07%) than 81.82% of its industry peers.
  • In the last couple of years the Gross Margin of CGM has declined.
Industry RankSector Rank
OM 5.75%
PM (TTM) N/A
GM 20.07%
OM growth 3Y-6.64%
OM growth 5Y-3.53%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.96%
GM growth 5Y-1.7%
CGM.PA Yearly Profit, Operating, Gross MarginsCGM.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 15 20

1

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CGM is still creating some value.
  • The number of shares outstanding for CGM has been increased compared to 1 year ago.
  • CGM has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, CGM has a worse debt to assets ratio.
CGM.PA Yearly Shares OutstandingCGM.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
CGM.PA Yearly Total Debt VS Total AssetsCGM.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of 1.27, we must say that CGM is in the distress zone and has some risk of bankruptcy.
  • CGM has a Altman-Z score (1.27) which is in line with its industry peers.
  • CGM has a debt to FCF ratio of 27.31. This is a negative value and a sign of low solvency as CGM would need 27.31 years to pay back of all of its debts.
  • CGM has a Debt to FCF ratio of 27.31. This is comparable to the rest of the industry: CGM outperforms 54.55% of its industry peers.
  • CGM has a Debt/Equity ratio of 1.14. This is a high value indicating a heavy dependency on external financing.
  • CGM has a Debt to Equity ratio of 1.14. This is in the lower half of the industry: CGM underperforms 72.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.14
Debt/FCF 27.31
Altman-Z 1.27
ROIC/WACC1.08
WACC4.14%
CGM.PA Yearly LT Debt VS Equity VS FCFCGM.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • CGM has a Current Ratio of 0.99. This is a bad value and indicates that CGM is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CGM has a worse Current ratio (0.99) than 63.64% of its industry peers.
  • A Quick Ratio of 0.97 indicates that CGM may have some problems paying its short term obligations.
  • CGM has a Quick ratio of 0.97. This is in the lower half of the industry: CGM underperforms 63.64% of its industry peers.
Industry RankSector Rank
Current Ratio 0.99
Quick Ratio 0.97
CGM.PA Yearly Current Assets VS Current LiabilitesCGM.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

3

3. Growth

3.1 Past

  • The earnings per share for CGM have decreased strongly by -97.97% in the last year.
  • Looking at the last year, CGM shows a small growth in Revenue. The Revenue has grown by 6.25% in the last year.
  • The Revenue has been growing slightly by 5.38% on average over the past years.
EPS 1Y (TTM)-97.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1194.13%
Revenue 1Y (TTM)6.25%
Revenue growth 3Y7.65%
Revenue growth 5Y5.38%
Sales Q2Q%6.51%

3.2 Future

  • The Earnings Per Share is expected to grow by 21.86% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, CGM will show a small growth in Revenue. The Revenue will grow by 3.41% on average per year.
EPS Next Y-1.77%
EPS Next 2Y20.1%
EPS Next 3Y21.86%
EPS Next 5YN/A
Revenue Next Year1.46%
Revenue Next 2Y2.88%
Revenue Next 3Y3.41%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CGM.PA Yearly Revenue VS EstimatesCGM.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
CGM.PA Yearly EPS VS EstimatesCGM.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2

5

4. Valuation

4.1 Price/Earnings Ratio

  • CGM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • CGM is valuated reasonably with a Price/Forward Earnings ratio of 9.28.
  • 90.91% of the companies in the same industry are more expensive than CGM, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of CGM to the average of the S&P500 Index (28.06), we can say CGM is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 9.28
CGM.PA Price Earnings VS Forward Price EarningsCGM.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CGM is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
  • CGM's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CGM is cheaper than 90.91% of the companies in the same industry.
Industry RankSector Rank
P/FCF 12.29
EV/EBITDA 3.23
CGM.PA Per share dataCGM.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30 40

4.3 Compensation for Growth

  • CGM's earnings are expected to grow with 21.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.1%
EPS Next 3Y21.86%

0

5. Dividend

5.1 Amount

  • CGM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CEGEDIM SA

EPA:CGM (9/3/2025, 7:00:00 PM)

10.4

-0.2 (-1.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)N/A
Earnings (Next)09-25
Inst Owners17.29%
Inst Owner ChangeN/A
Ins Owners57.12%
Ins Owner ChangeN/A
Market Cap146.64M
Revenue(TTM)654.50M
Net Income(TTM)-14.71M
Analysts48.89
Price Target12.92 (24.23%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.56%
PT rev (3m)-7.32%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-24.49%
EPS NY rev (3m)-24.49%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.28
P/S 0.22
P/FCF 12.29
P/OCF 1.44
P/B 0.55
P/tB N/A
EV/EBITDA 3.23
EPS(TTM)-1.07
EYN/A
EPS(NY)1.12
Fwd EY10.78%
FCF(TTM)0.85
FCFY8.14%
OCF(TTM)7.22
OCFY69.45%
SpS46.42
BVpS18.75
TBVpS-11.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1.49%
ROE -5.56%
ROCE 6.06%
ROIC 4.46%
ROICexc 4.84%
ROICexgc 19.22%
OM 5.75%
PM (TTM) N/A
GM 20.07%
FCFM 1.82%
ROA(3y)-0.25%
ROA(5y)0.74%
ROE(3y)-1.16%
ROE(5y)2.61%
ROIC(3y)2.87%
ROIC(5y)3.89%
ROICexc(3y)3.13%
ROICexc(5y)4.15%
ROICexgc(3y)11.62%
ROICexgc(5y)15.26%
ROCE(3y)3.91%
ROCE(5y)5.29%
ROICexgc growth 3Y0.21%
ROICexgc growth 5Y-3.19%
ROICexc growth 3Y-3.24%
ROICexc growth 5Y-2.52%
OM growth 3Y-6.64%
OM growth 5Y-3.53%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.96%
GM growth 5Y-1.7%
F-Score3
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 1.14
Debt/FCF 27.31
Debt/EBITDA 2.3
Cap/Depr 96.22%
Cap/Sales 13.74%
Interest Coverage 4.24
Cash Conversion 77.7%
Profit Quality N/A
Current Ratio 0.99
Quick Ratio 0.97
Altman-Z 1.27
F-Score3
WACC4.14%
ROIC/WACC1.08
Cap/Depr(3y)92.57%
Cap/Depr(5y)94.88%
Cap/Sales(3y)13.24%
Cap/Sales(5y)13.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-97.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1194.13%
EPS Next Y-1.77%
EPS Next 2Y20.1%
EPS Next 3Y21.86%
EPS Next 5YN/A
Revenue 1Y (TTM)6.25%
Revenue growth 3Y7.65%
Revenue growth 5Y5.38%
Sales Q2Q%6.51%
Revenue Next Year1.46%
Revenue Next 2Y2.88%
Revenue Next 3Y3.41%
Revenue Next 5YN/A
EBIT growth 1Y79.81%
EBIT growth 3Y0.5%
EBIT growth 5Y1.66%
EBIT Next Year278.79%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-46.81%
FCF growth 3Y-27.43%
FCF growth 5YN/A
OCF growth 1Y4.01%
OCF growth 3Y2%
OCF growth 5Y28.33%

CEGEDIM SA / CGM.PA FAQ

What is the fundamental rating for CGM stock?

ChartMill assigns a fundamental rating of 3 / 10 to CGM.PA.


What is the valuation status of CEGEDIM SA (CGM.PA) stock?

ChartMill assigns a valuation rating of 5 / 10 to CEGEDIM SA (CGM.PA). This can be considered as Fairly Valued.


What is the profitability of CGM stock?

CEGEDIM SA (CGM.PA) has a profitability rating of 3 / 10.


Can you provide the dividend sustainability for CGM stock?

The dividend rating of CEGEDIM SA (CGM.PA) is 0 / 10 and the dividend payout ratio is 0%.